Despite the lack of ongoing trials of anti-MARCO mAbs, the combination of approaches, whereby both the immune system and specific cancer antigens are targeted, may prove to be a successful mechanism to target specific tumor resident macrophage subsets and to repolarize them. Here, MARCO is linked to neoplasm.